Dbv Technologies Sa-spon Adr (DBVT) Smart Money Holdings (13F, Q2 2026)

DBVT ranks #5144 out of 37696 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

78 institutions disclose a position in DBVT, but none treat it as a major bet — even MPM BioImpact LLC, its most concentrated holder, allocates just 3.7% of its own portfolio to it.

GAMMA Investing LLC has trimmed its DBVT position for two straight quarters, cutting it by $29.9K while still holding $30.7K.

DBVT is down 0.7% today, but institutions show net buying of $14.6M this quarter — a divergence between today's price move and the underlying institutional flow.

DBVT reported a net loss of $176.0M over the trailing twelve months.

• Not yet profitable — net loss of $176.0M over the trailing twelve months
• Revenue grew 29.3% year over year
• Net income declined year over year, from -$122.5M to -$176.0M
• Operating cash flow was negative, using $121.2M in cash
• Current ratio of 3.67x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.38x equity — within a conventional range